LLY vs RGNX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Regenxbio faces a significantly elevated risk profile since the last analysis. While its proprietary NAV gene therapy platform and the lead asset RGX-314 (wet AMD) with the AbbVie partnership still offer multi-billion dollar market potential, recent events have introduced substantial uncertainty. The FDA clinical holds on two key pipeline assets (RGX-111 and RGX-121), including a neoplasm case, ra...